Search Results
Young Advocate, Big Goals: Charlotte’s Story
Imagine going to the doctor for a cold only to learn you actually have leukemia. That’s how Charlotte's experience with blood cancer began in 2018.
“The doctor diagnosed it as strep throat,” Charlotte remembers. When the antibiotics didn’t work, she “went to another doctor who diagnosed it as something else.”
IRONMAN World Championships: 5-Star Team Races for Cancer Cures
After months of rigorous training, all five LLS Team In Training teammates finished at the 2017 IRONMAN World Championships in Kona, Hawaii on October 7. The team came together from across the U.S. and Canada to compete in the 140.6 mile iconic triathlon – raising an incredible $435,000 and counting, for blood cancer cures.After months of rigorous training, all five LLS Team In Training teammates finished at the 2017 IRONMAN World Championships in Kona, Hawaii on October 7. The team came together from across the U.S.
Companies Take on Blood Cancer
Corporations usually have enough on their plate, just taking care of business, but at least one has found a creative way to also help generate millions of dollars to fund blood cancer research, education and patient services.
Ushering In a New Era of Pediatric Blood Cancer Treatment and Care
We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures and better care to children with blood cancer through The LLS Children’s Initiative.
Tell us about The LLS Children’s Initiative and why it’s so important to you and LLS.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.DEVELOPING RELATIONSHIPS ON CAPITOL HILL
As the voice for all blood cancer patients, The Leukemia & Lymphoma Society (LLS) establishes and grows meaningful relationships with policymakers
The Leukemia & Lymphoma Society is committed to removing barriers to care for blood cancer patients, and works with federal and state legislators to advocate for policies to ensure patients have access to quality, affordable care and treatments they need.
Here’s an inside look at how we cultivate these key connections:
High Hopes: How a Rising Star Basketball Player’s Story is Bringing Light to the Darkness of Cancer
Each year, from September to November, thousands of illuminated lanterns light up the sky across the country as part of The Leukemia & Lymphoma Society’s Light The Night fundraising campaign – all to end cancer. For one rising star basketball player and Light The Night Honored Hero, Maurice Smith, taking steps to end cancer gave him, and so many others, high hopes for a brighter future.
Researcher Q&A: Christopher Cogle, M.D., University of Florida
Christopher Cogle, M.D., Professor of Medicine, University of Florida, Pierre Chagnon Professor of Stem Cell Biology and Bone Marrow Transplant, is the recipient of an LLS Scholar in Clinical Research grant through our Career Development Program. He also has a project supported through LLS’s Therapy Acceleration Program. Dr. Cogle explains his work advancing an investigational approach to treating patients with acute myeloid leukemia and myelodysplastic syndromes.
Blood Cancer Research Poised for Another ‘Banner Year’ in 2024
More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.
6-Thioguanine
6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Progress and Challenges in Treating the Blood Cancers: #ASH19
It’s that time of year again, when more than 30,000 scientists specializing in blood cancers and other blood disorders, oncologists and hematologists, pharmaceutical and biotechnology company representatives, and cancer patient advocacy organizations gather in one place to learn about the latest progress in treatments and share new ideas.
This year, we’re in sunny Orlando for the 61st ASH (American Society of Hematology) Annual meeting and Exposition.